Porcine reproductive and respiratory syndrome or also known by its acronym in English PRRS, is a disease of viral origin that seriously affects pig production, causing great disproportionate economic and productive losses worldwide, this due to the fact that the virus has an RNA genome, as a result of being in constant mutation, thus presenting a great genomic variation that makes it difficult to control and eradicate this disease, for which various studies have been carried out to mitigate the impact of this disease; There are several commercial agents that use the attenuated virus and others the inactivated virus. Among the most used are those that contain the “live or attenuated” virus, with many laboratories selling their own prototypes, and among the best known and oldest is the Ingelvac PRRS® MLV vaccine from the Boehringer Ingelheim laboratory, which has had many controversies since the years for the effectiveness it produces against immunity to the PRRS virus against damage at the lobular level of the lungs, for which in the present work articles that correspond from 2016 to 2022 on the functionality of this vaccine will be investigated. and its pros and cons with immune-mediated protection from this virus.